FreeCME

Changing Landscape of Treatment Options for ALL with CD19, CD22 Monoclonal Antibodies and AML with IDH1/2, FLT3, CD33 and Hedgehog Pathway Targeted Agents

CME: 1.0

September 17, 2019
/ Print / Reprints /
| Share More
/ Text Size+

Post a comment to this article